Although commonly used tests for women with newly diagnosed breast cancer include estrogen and progesterone receptors and HER2 status, which have both prognostic and predictive value, comparable molecular markers are not available for men with a diagnosis of prostate cancer. The gene discussed is ERBB2; the disease is prostate carcinoma.